Immune checkpoint inhibitor chemotherapy in non-small cell lung cancer

While the combination of an immune checkpoint inhibitor and chemotherapy has become a standard treatment for non-small cell lung cancer, there are few data on its value in subjects over 75. In this multicenter retrospective cohort study, Japanese researchers evaluated the efficacy and safety of this first-line therapeutic strategy in elderly non-small-cell lung cancer. A total of 1,245 patients were included in the study. No difference in overall survival or progression-free survival was found between patients receiving chemotherapy alone or in combination with an immune checkpoint inhibitor.